Welcome to our dedicated page for ARS Pharmaceuticals SEC filings (Ticker: SPRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARS Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARS Pharmaceuticals's regulatory disclosures and financial reporting.
ARS Pharmaceuticals, Inc. (SPRY) had a Form 144 filed on behalf of Sarina Tanimoto, indicating an intended sale of 25,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an anticipated sale date of 08/20/2026, in connection with a stock option exercise for cash. Over the prior three months, Sarina Tanimoto reported sales of additional common shares of ARS Pharmaceuticals.
ARS Pharmaceuticals, Inc. (SPRY) received a notice that Richard Lowenthal intends to sell common stock under Rule 144. The planned sale is 25,000 shares of common stock on 08/20/2026, to be sold through Morgan Stanley Smith Barney LLC after a stock option exercise.
The filing reports an aggregate market value for these securities of $148,160.00. It also lists prior sales by Richard Lowenthal in the last three months: 50,000 shares of common stock sold on 08/19/2026 for $322,345.00 and 50,000 shares sold on 08/18/2026 for $315,885.00.
ARS Pharmaceuticals, Inc. (SPRY) received a notice under Rule 144 that Sarina Tanimoto, identified on the form as an officer or 10% stockholder, intends to sell company common stock. The notice covers 25,000 shares of common stock, to be acquired from the issuer via a stock option exercise for cash and proposed for sale on or about 08/19/2026 through Morgan Stanley Smith Barney LLC on NASDAQ. The form also reports that Tanimoto sold 49,401 common shares during the prior three months for aggregate proceeds of $311,191.72.
ARS Pharmaceuticals, Inc. (SPRY) received a Rule 144 notice from Richard Lowenthal covering a proposed sale of up to 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $322,345.00 as of 08/19/2026 on NASDAQ. The shares are to be sold for cash in connection with a stock option exercise with the issuer. The filing also notes that Lowenthal sold 50,000 shares of common stock on 08/18/2026 for aggregate proceeds of $315,885.00 during the preceding three months.
ARS Pharmaceuticals, Inc. (SPRY) received a Rule 144 notice from stockholder Sarina Tanimoto covering a planned sale of up to 49,401 shares of common stock. The shares are tied to a stock option exercise for cash and are expected to be sold through Morgan Stanley Smith Barney LLC on or after 08/18/2026, with an indicated aggregate market value of $311,191.72 at the time of the notice.
ARS Pharmaceuticals, Inc. (SPRY) received a Rule 144 notice from Richard Lowenthal covering up to 50,000 shares of common stock. The shares relate to a stock option exercise for cash with a stated aggregate market value of $315,885.00, with a proposed sale date of 08/18/2026 through Morgan Stanley Smith Barney LLC on Nasdaq.
ARS Pharmaceuticals, Inc. reported an initial insider ownership filing for executive Margaret Ekins Smith, who serves as Chief Commercial Officer. The Form 3 shows no reportable transactions and no holdings entries at the time of this filing.
ARS Pharmaceuticals, Inc. reported strong top-line growth but significantly higher losses for the quarter and six months ended June 30, 2026. Total revenue for the quarter rose to $33.7 million from $15.7 million a year earlier, driven mainly by higher net product revenue from neffy and increased supply revenue. For the first half of 2026, revenue was $56.3 million versus $23.7 million in 2025.
Operating expenses expanded sharply, with selling, general and administrative costs of $77.6 million in the quarter and $149.8 million year‑to‑date, including advertising spend of $31.0 million and $67.4 million, respectively. The company posted a quarterly net loss of $62.3 million and a six‑month net loss of $123.0 million, both wider than in 2025, and used $105.9 million of cash in operating activities in the first half.
As of June 30, 2026, ARS held $143.8 million in cash, cash equivalents and short‑term investments, term loans of $96.7 million, and a financing liability of $74.9 million related to its ALK collaboration. Management states that existing liquidity is sufficient to meet anticipated cash requirements for at least 12 months after issuance of the financial statements, while the business remains highly dependent on the commercialization of neffy and on key collaboration agreements.
ARS Pharmaceuticals reported second quarter 2026 total revenue of $33.7 million, up from $15.7 million a year earlier, driven by U.S. neffy net product revenue of $26.2 million and additional collaboration and supply revenue. neffy captured a 5% share of the U.S. epinephrine market for Type 1 allergies and an 8% share within field‑targeted accounts, with more than 16,000 unique prescribers in the quarter.
Total operating expenses reached $95.1 million, including $77.6 million of SG&A and $4.7 million of R&D, resulting in a net loss of $62.3 million or ($0.63) per share. Cash, cash equivalents and short‑term investments were $143.8 million as of June 30, 2026. The company plans aggregate SG&A and R&D expenses of $114–$126 million for the second half of 2026, implying more than a 40% reduction in cash‑based SG&A from the first half, and anticipates a path to cash flow breakeven by the end of 2027. ARS is also advancing its intranasal epinephrine program ARS‑2 in chronic spontaneous urticaria, with interim Phase 2b data expected in the first quarter of 2027.
BlackRock, Inc. reports beneficial ownership of common stock of ARS Pharmaceuticals, Inc.. BlackRock and certain of its business units beneficially own 5,218,264 shares of ARS Pharmaceuticals common stock, representing 5.3% of the outstanding class. BlackRock has sole voting power over 5,126,277 shares and sole dispositive power over all 5,218,264 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no single client has more than five percent of ARS Pharmaceuticals’ outstanding common shares.